Juno Therapeutics Inc. (NASDAQ:JUNO) belonging to the Medical sector has surged 9.14% and closed its last trading session at $23.4.
The company reported its EPS on 11/09/2016. Currently, the stock has a 1 Year Price Target of $30.5.
The consensus recommendation, according to Zacks Investment research, is 2.27. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2.33 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.3 and 1.78 respectively.
Juno Therapeutics Inc. on 11/09/2016 reported its EPS as $-0.57 with the analysts projecting the EPS of the stock as $-0.55. The company beat the analyst EPS Estimate with the difference of $-0.02. This shows a surprise factor of -3.6%.
Many analysts have provided their estimated foresights on Juno Therapeutics Inc. Earnings, with 9 analysts believing the company would generate an Average Estimate of $-0.61.
Whereas they predicted High and Low Earnings Estimate as $-0.39 and $-0.79 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.53.
Analysts are also projecting an Average Revenue Estimate for Juno Therapeutics Inc. as $14.56 Million in the Current Quarter. This estimate is provided by 11 analysts.
The High Revenue estimate is predicted as 20.3 Million, while the Low Revenue Estimate prediction stands at 7.5 Million. The company’s last year sales total was 4.15 Million.
For the Current Quarter, the growth estimate for Juno Therapeutics Inc. is -15.1%, while for the Next Quarter the stock growth estimate is -2.6%.
The Company got Initiated by Wells Fargo on 22-Feb-17 to Outperform.
Insider Trades for Juno Therapeutics Inc. show that the latest trade was made on 6 Feb 2017 where Cassidy (Bernard J), the General Counsel completed a transaction type “Buy” in which 24390 shares were traded at a price of $0.
13 Insider Sales transactions were made totaling 1791420 shares traded.
12 analysts projected Price Targets for Juno Therapeutics Inc.. The analysts believe that the company stock price could grow as high as $41. The Low Price target projection by analysts is $23 and the Mean Price Target is $30.5.
Juno Therapeutics Inc. (NASDAQ:JUNO) has the market capitalization of $2.56 Billion. The company rocked its 52-Week High of $49.72 on Jun 6, 2016 and touched its 52-Week Low of $17.52 on Dec 22, 2016.
The stock has Return on Assets (ROA) of -19 percent. Return on Equity (ROE) stands at -24% and Return on Investment (ROI) of -20.3 percent.
The stock is currently showing YTD performance of 24.14 Percent. The company has Beta Value of 0 and ATR value of 1.06. The Weekly and Monthly Volatility stands at 5.58% and 4.94%.